Former US Senator Jeff Flake and Brandon Allgood, PhD, will be the keynote speakers at the 2019 installment of CPhI North America, in Chicago, IL.
On April 16, 2019, CPhI North Americaannounced former US Senator Jeff Flake and Brandon Allgood, PhD, chief technology officer and co-founder at Numerate, as its keynote speakers for its 2019 event, taking place from April 30–May 2, 2019 in Chicago, IL.
Senator Flake has nearly two decades of experience on Capitol Hill in both the Senate and the House of Representatives. During his presentation, Flake will share his views on pharma manufacturing, healthcare innovation, and the direction of healthcare as he sees it under the current structure of government, as well as his viewpoint on scenarios beyond 2020.
“Both political parties understand the potency of healthcare as a campaign issue, but in the short term we can expect both parties to play to their base with no significant policy changes-especially in an era of divided government,” said Senator Flake on the current state of the industry in a CPhI North America press release. “And in the long-term, the pharmaceutical industry will likely continue its efforts to find new wonder drugs while policymakers grapple with impatient constituents struggling with high prescription drug costs.”
As the chief technology officer and co-founder of Numerate, a company that uses drug discovery data and artificial intelligence (AI) algorithms to accelerate and optimize the drug discovery process, Allgood currently leads research and development for Numerate’s AI platform. He has 15 years of experience in AI, mathematical modeling, and large-scale cloud and distributed computing. Allgood’s presentation will discuss innovation from a technology perspective as well as introduce the topic of AI and how it is already being used in the pharmaceutical industry. He will also share his opinion on where the industry needs to head, what organizations need to consider for the increasing implementation of AI, and what the industry is currently doing to get there.
“AI is changing the way pharma performs research and conducts business, but most within pharma still don't have a good grasp of what AI is (and isn't) and how it can be applied effectively,” said Allgood in the press release. “During my keynote, I will introduce the topic in a grounded way because those organizations and people that don't come up to speed on AI will likely be left behind.”
Both keynotes support the event’s central theme, “Fostering Innovation in Drug Development and Manufacturing in a New Era of Regulation”. Senator Flake’s keynote will take place on Tuesday, April 30 from 1:30pm–2:15pm, and Allgood will present his keynote during the same time slot on Wednesday, May 1. Both presentations will be open to all pass types. To learn more, visit www.CPhINorthAmerica.com.
Source: CPhI North America
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.